FNAM (Evolutionary Genomics) Accumulated Depreciation: $-0.50 Mil (As of Dec. 2022)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FNAM Evolutionary Genomics Inc FNAM
31 GF Score
Price $0.00
View Full Analysis

What is Evolutionary Genomics Accumulated Depreciation?

Evolutionary Genomics FNAM 31 Accumulated Depreciation is $-0.50 Mil as of Dec. 2022. GuruFocus rates FNAM with a GF Score™ of 31/100.

Note: A negative number here means the assets are depreciated. When depricates more, the absolute value gets bigger.

Evolutionary Genomics's quarterly accumulated depreciation increased from Jun. 2022 ($-0.49 Mil) to Sep. 2022 ($-0.50 Mil) and increased from Sep. 2022 ($-0.50 Mil) to Dec. 2022 ($-0.50 Mil).

Evolutionary Genomics's annual accumulated depreciation increased from Dec. 2020 ($-0.45 Mil) to Dec. 2021 ($-0.49 Mil) and increased from Dec. 2021 ($-0.49 Mil) to Dec. 2022 ($-0.50 Mil).

Evolutionary Genomics Accumulated Depreciation Related Terms

Evolutionary Genomics Accumulated Depreciation Historical Data

* Premium members only.

The historical data trend for Evolutionary Genomics's Accumulated Depreciation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Evolutionary Genomics Accumulated Depreciation Chart

Evolutionary Genomics Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Accumulated Depreciation
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.38 -0.42 -0.45 -0.49 -0.50

Evolutionary Genomics Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Accumulated Depreciation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.49 -0.49 -0.49 -0.50 -0.50
FNAM
31GF Score
Evolutionary Genomics Inc FNAM
Accumulated Depreciation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Evolutionary Genomics Accumulated Depreciation Calculation

The cumulative depreciation of an asset up to a single point in its life. Regardless of the method used to calculate it, the depreciation of an asset during a single period is added to the previous period's accumulated depreciation to get the current accumulated depreciation.

What does a Accumulated Depreciation of $-0.50 Mil mean?
Evolutionary Genomics (FNAM) has a Accumulated Depreciation of $-0.50 Mil as of Dec. 2022. Accumulated depreciation is a contra-asset item that accounts for the decline in value of long-term assets. View historical data on Evolutionary Genomics and its competitors.
Is Evolutionary Genomics' Accumulated Depreciation too high?
Evolutionary Genomics' current Accumulated Depreciation is $-0.50 Mil. Overall, Evolutionary Genomics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Evolutionary Genomics' Accumulated Depreciation compare to BXRX and GNCA?
Evolutionary Genomics' Accumulated Depreciation of $-0.50 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accumulated Depreciation for a Biotechnology company?
A good Accumulated Depreciation depends on the Biotechnology industry context. However, Accumulated Depreciation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accumulated Depreciation mean?
A high Accumulated Depreciation can signal that a stock is expensive relative to its fundamentals. Accumulated depreciation is a contra-asset item that accounts for the decline in value of long-term assets. View historical data on Evolutionary Genomics and its competitors. Evolutionary Genomics's current Accumulated Depreciation is $-0.50 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evolutionary Genomics stock overvalued right now?
Evolutionary Genomics (FNAM) has a current Accumulated Depreciation of $-0.50 Mil. The current Accumulated Depreciation is $-0.50 Mil. Evolutionary Genomics' overall GF Score™ is 31/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accumulated Depreciation calculated?
Accumulated Depreciation is calculated from a company's financial statements. For Evolutionary Genomics (FNAM), the current Accumulated Depreciation is $-0.50 Mil as of Dec. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Evolutionary Genomics Business Description

Address 4220 Morning Star Drive, Castle Rock, CO, USA, 80108
Evolutionary Genomics Inc is involved in the development of a technology platform, the Adapted Traits Platform (ATP), to identify commercially valuable genes that control important traits in animals and plants. It uses the ATP to identify genes to improve crop plant traits such as yield, sugar content, biomass, drought tolerance, and pest/disease resistance. The company's platform identifies key genes that have changed successfully to impart new or improved traits. Its primary source of revenue had been contract services revenue for research performed by it on behalf of other commercial entities and grant income received from governmental agencies, industry associations and grant-making foundations for research performed.
31GF Score

Get the complete analysis for FNAM

Accumulated Depreciation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price